---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-013276"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2023-04-18T23:59:59+00:00"
generated_at: "2026-06-17T00:48:44.902492+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics announces ulcerative colitis trial for CP101, amends UMN license

## Summary
- Investigator-sponsored trial at Brigham and Women's Hospital comparing two doses of CP101 in mild-to-moderate ulcerative colitis; topline data expected in 2025.
- Amendment to University of Minnesota license allows Finch to satisfy performance milestones via sublicensing, aligning with new partnership-focused strategy.
- Finch exclusively licenses 13 issued patents and 7 patent applications covering human fecal microbe formulations and microbiota diversity methods.
- Clinical trial designed to generate data on safety, PK, PD, and clinical efficacy, building on microbiome evidence in ulcerative colitis.

## SEC filing metadata
- accession: 0000950170-23-013276
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2023-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017023013276/0000950170-23-013276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017023013276/fnch-20230412.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-013276
- JSON: https://secwatch.observer/filing/0000950170-23-013276.json
- Plain text: https://secwatch.observer/filing/0000950170-23-013276.txt

## Key facts
- Material Agreements
  Finch Therapeutics Group, Inc. amended Amended and Restated Exclusive License Agreement with Regents of the University of Minnesota valued at amended terms related to performance milestones, including extension of deadlines and expansion of r (effective 2023-04-12).
  - Action: amendment
  - Agreement: license
  - Counterparty: Regents of the University of Minnesota
  - Value: amended terms related to performance milestones, including extension of deadlines and expansion of r
  - Effective: 2023-04-12
  source text: On April 12, 2023, Finch Therapeutics Holdings LLC (“FTH”), a direct, wholly owned subsidiary of Finch Therapeutics Group, Inc. (the “Company”), and the Regents of the University of Minnesota (“UMN”), entered into an amendment (the “Amendment”) to the Amended and Restated Exclusive License Agreement, dated January 28, 2022, between FTH and UMN (the “UMN Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000095017023013276/0000950170-23-013276-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.